Skip to content

HUTCHMED (China) Ltd

HCM· NasdaqCore metricsCIK 1648257

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -1.36%
Market cap
$2.60B
174.47M shares
Filings
612
$548.51M
FY 2025−13.0% FY25 yoy
$456.91M
FY 2025+1,111.0% FY25 yoy
-$39.16M
FY 2025N/M FY25 yoy
-$78.81M
FY 2025derivedN/M FY25 yoy
$0.52
FY 2025+1,200.0% FY25 yoy
$71.33M
FY 2025−53.7% FY25 yoy
$2.60B
5.7×
4.7×
2.1×
-3.03%
—

FY2025 figures · derived

Price

$14.902.46%$0.38past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$548.51MFY 2025
$838.00M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$548,512,000reported
FY 20242024-12-31$630,201,000reported
FY 20232023-12-31$837,999,000reported
FY 20222022-12-31$426,409,000reported
FY 20212021-12-31$356,128,000reported
FY 20202020-12-31$227,976,000reported
FY 20192019-12-31$204,890,000reported
FY 20182018-12-31$214,109,000reported
FY 20172017-12-31$241,203,000reported
FY 20162016-12-31$216,080,000reported
FY 20152015-12-31$178,203,000reported
FY 20142014-12-31$87,329,000reported

Capital returns

Dividends and buybacks · FY2015 to FY2024
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2024—$36.06M$36.06M—871.60M sh+0.0%—
FY2023—$9.07M$9.07M—871.26M sh+0.7%4.9%
FY2022—$48.08M$48.08M—864.78M sh+0.0%—
FY2021—$27.31M$27.31M—864.53M sh+18.8%—
FY2020—$12.90M$12.90M—727.72M sh+9.1%—

Segments

Revenue by Segments, FY2018 to FY2025FY2018Oncology/Immunology segment · FY2018 · $41.23MOther Ventures segment · FY2018 · $172.88MFY2019Oncology/Immunology segment · FY2019 · $26.79MOther Ventures segment · FY2019 · $178.10MFY2020Oncology/Immunology segment · FY2020 · $30.22MOther Ventures segment · FY2020 · $197.76MFY2021Oncology/Immunology segment · FY2021 · $119.61MOther Ventures segment · FY2021 · $236.52MFY2022Oncology/Immunology segment · FY2022 · $163.84MOther Ventures segment · FY2022 · $262.57MFY2023Oncology/Immunology segment · FY2023 · $528.62MOther Ventures segment · FY2023 · $309.38MFY2024Oncology/Immunology segment · FY2024 · $363.37MOther Ventures segment · FY2024 · $266.84MFY2025Oncology/Immunology segment · FY2025 · $285.54MOther Ventures segment · FY2025 · $262.97M
LineFY2025ShareChange
Oncology/Immunology segment$285.54M52%−21.4%
Other Ventures segment$262.97M48%−1.4%
Total$548.51M

From the 20-F filed Mar 5, 2026HCM

Pharmaceutical preparations

HUTCHMED (China) Ltd is the 53rd largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

HUTCHMED (China) Ltd · CIK 1648257 · Engraved from SEC EDGAR